2 recruiting, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow LAM-001: new trials by email Literature Review of LAM-001 trials Research Report on LAM-001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension | Phase 2 | Not yet recruiting | IRulya Therapeutics Inc. | 60 | 2026-12-01 | 2026-10-21 |
| LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Placebo, LAM-001 - Pulmonary Hypertension Due to Lung Diseases and Hypoxia | Phase 2 | Recruiting | IRulya Therapeutics Inc. | 85 | 2023-08-30 | 2026-10-15 |
| LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. LAM-001, Placebo - Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction | Phase 2 | Recruiting | Steven Hays, MD | 30 | 2023-08-17 | 2026-05-18 |
Bronchiolitis Obliterans Syndrome (1) · Hypoxia (1) · Lung Diseases, Interstitial (1) · Sarcoidosis (1)
IRulya Therapeutics Inc. (2) · Steven Hays, MD (1)
United States (3)
Steven Hays, MD (1)